Recursion Pharma

A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

Launch date

Nov 2013

Employees

501-1000 people

Market cap

Net debt

Enterprise valuation

$2.0b (Public information from Jul 2024)

Salt Lake City Utah (HQ)

https://www.recursion.com/

https://twitter.com/recursionpharma https://www.facebook.com/recursionpharma https://www.linkedin.com/company/recursion-pharmaceuticals/

View job openings

Deals in current and previous year:

- view all (2)

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	0000	0000	0000	0000	0000	0000	0000
% growth	99 %	193 %	297 %	11 %	23 %	13 %	150 %
EBITDA	0000	0000	0000	0000	0000	0000	0000
% EBITDA margin	(2353 %)	(1828 %)	(619 %)	(701 %)	(758 %)	(834 %)	(330 %)
Profit	0000	0000	0000	0000	0000	0000	0000
% profit margin	(2549 %)	(1865 %)	(604 %)	(748 %)	(761 %)	(793 %)	(263 %)
EV / revenue	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
EV / EBITDA	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
R&D budget	0000	0000	0000	0000	0000	0000	0000
R&D % of revenue	1855 %	1353 %	392 %	550 %	-	-	-

Get premium to view all results

Date	Investors	Amount	Round
-	investor investor investor investor investor investor investor investor investor investor	$0.0	round
Jul 2019	investor investor investor investor investor investor investor investor investor investor investor investor	$0.0	round
Sep 2020	investor investor investor investor investor investor investor investor investor	$0.0 Valuation: $0.0 584.5x EV/LTM Revenues -17.2x EV/LTM EBITDA	round
Apr 2021	N/A	$0.0 Valuation: $0.0 791.1x EV/LTM Revenues -33.6x EV/LTM EBITDA	round
Oct 2022	investor investor investor investor investor investor	$0.0	round
Jul 2023	investor	$0.0	round
Jun 2024*	N/A	$200m	Post IPO Equity
Total Funding		000k